Haleon growth below expectations on weak cold & flu season

Haleon_Shopper_Science_Voltarol_101

Organic revenue growth came in lower than expectations for 2025 at 3%, with the performance also affected by depressed consumer confidence in North America, where volumes declined 1.4%

A drop-off in demand for cold & flu medication has held back growth at consumer health group Haleon.

Already have an account? Sign in here

Want access to this article?

Register for LIMITED access

REGISTER FOR FREE

Get PREMIUM access for £1 a week

SUBSCRIBE NOW